The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats

Peritoneal Dialysis International

Volumn 27, Issue 4, 2007, Pages 424-431

  Ersoy, Rifki ^a   Celik, Ali ^a   Yilmaz, Osman ^a   Sarioglu, Sulen ^a   Sis, Banu ^a   Akan, Pinar ^a   Yenicerioglu, Yavuz ^a   Ormen, Murat ^a   Camsari, Taner ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Irbesartan; Peritoneal fibrosis; Peritonitis; Spironolactone; TGF 1

Indexed keywords

DEXTRAN; IRBESARTAN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PERITONITIS; BACTERIAL STRAIN; BACTERIUM ADHERENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; MONOTHERAPY; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEUM; PERITONEUM ADHESION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RAT; STAPHYLOCOCCUS AUREUS;

EID: 34547623254     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700410     Document Type: Article

References (34)

1. Coles GA, Williams JD, Topley N. Peritoneal inflammation and long-term changes in peritoneal structure and function. In: Gokal R, Khanna R, Krediet RT, Nolph KD, eds. Textbook of Peritoneal Dialysis. 2nd ed. Dordrecht: Kluwer Academic Publishers; 2000: 566-83.
2. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
4. Flessner MF, Choi J, Vanpelt H, He Z, Credit K, Henegar J, et al. Correlating structure with solute and water transport in a chronic model of peritoneal inflammation. Am J Renal Physiol 2006; 290:F232-F240.
5. Pollock CA, Ibels LS, Eckstein RP, Graham JC, Caterson RJ, Mahony JF, et al. Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989; 9:198-204.
6. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
7. Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52:524-9.
8. Topley N, Liberek T, Davenport A, Li FK, Fear H, Williams JD. Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int Suppl 1996; 56: S17-21.
9. Jorres A, Ludat K, Sander K, Dunkel K, Lorenz F, Keck H, et al. The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int Suppl 1996; 56:S22-7.
10. Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160: 2285-94.
11. Beavis MJ, Williams JD, Hoppe J, Topley N. Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 1997; 51:205-15.
12. Jorres A, Ludat K, Lang J, Sander K, Gahl GM, Frei U, et al. Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 by proinflammatory cytokines. J Am Soc Nephrol 1996; 7:2192-201.
13. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331:1286-92.
14. Border WA, Noble N. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001; 21:563-72.
15. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997; 17: 467-91.
16. Gambaro G, Weigert C, Ceol M, Schleicher ED. Inhibition of transforming growth factor-β1 gene overexpression as a strategy to prevent fibrosis. Contrib Nephrol 2001; 131: 107-13.
17. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33: 105-10.
18. Hung KY, Shyu RS, Fang CC. Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int 2001; 59:2316-24.
19. Duman S, Günal AI, Sen S, Asci G. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2000; 21:219-24.
20. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of lisinopril versus valsartan on peritoneal alterations in rats. Int J Artif Organs 2005; 28:156-63.
21. Coronel F, Berni A, Cigarran S, Calvo N, Herrero JA. Effects of angiotensin II receptor blocker (irbesartan) on peritoneal membrane functions. Adv Perit Dial 2004; 20: 27-30.
22. Fabiani ME, Dinh DT, Nassis L, Casley DJ, Johnston CI. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration. Clin Sci 2000; 99:331-41.
23. Shiga T, Fujimura A, Ebihara A. Administration time-dependent change in the effect of spironolactone in rats. Jpn J Pharmacol 1994; 65:179-81.
24. Ghellai AM, Stucchi AF, Chegini N, Ma C, Andry CD, Kaseta JM, et al. Role of transforming growth factor beta-1 in peritonitis-induced adhesions. J Gastrointest Surg 2000; 4:316-23.
25. Border WA, Noble NA. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998; 31:181-8.
26. Ibrahim HN, Rosenberg ME, Hostett TH. Role of reninangiotensin-aldosterone system in the progression of renal disease. A critical review. Semin Nephrol 1997; 17: 431-40.
27. Peters H, Border WA, Nobre NA. Targeting TGF-β overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-80.
28. Pimentel JL, Sundell CL, Wang SS, Kopp JB, Montero A, Martinez-Maldonado M, et al. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int 1995; 48: 1233-46.
29. Lin CY, Chen WP, Yang LY, Chen A, Huang TP. Persistent transforming growth factor beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Adv Perit Dial 1997; 13:64-71.
30. Hatakeyama H, Miyamori L, Fujita T, Takeda Y, Takeda R, Yamamuto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269:24316-20.
31. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93:2578-83.
32. Duprez D, De Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2:327-34.
33. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37:677-88.
34. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A.